tiprankstipranks
Candel Therapeutics Shows Promising Pancreatic Cancer Trial Results
Company Announcements

Candel Therapeutics Shows Promising Pancreatic Cancer Trial Results

Don't Miss Our Christmas Offers:

Candel Therapeutics (CADL) just unveiled an update.

Candel Therapeutics, Inc. has revealed promising interim results from a phase 2 trial of CAN-2409 for treating non-metastatic pancreatic cancer, showing notably improved survival rates compared to the control group. Patients treated with CAN-2409 experienced a median overall survival of nearly 29 months, a stark contrast to the 12.5 months in the control group. Moreover, the treatment induced a significant immune response and maintained a favorable safety profile, bolstering hope for its potential as a viable therapeutic option.

See more data about CADL stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyCandel Therapeutics Inc call volume above normal and directionally bullish
TheFlyCandel Therapeutics price target raised to $19 from $11 at H.C. Wainwright
TheFlyCandel Therapeutics Inc call volume above normal and directionally bullish
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App